Rivaroxaban and Embolism - a phase IV clinical study of FDA data

Summary:

Embolism is reported as a side effect among people who take Rivaroxaban (rivaroxaban), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Apixaban, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Embolism when taking Rivaroxaban. It is created by eHealthMe based on reports of 26,430 people who have side effects when taking Rivaroxaban from the FDA, and is updated regularly.

What is Rivaroxaban?

Rivaroxaban has active ingredients of rivaroxaban. It is often used in blood clots. eHealthMe is studying from 26,544 Rivaroxaban users. Check the latest studies of Rivaroxaban.

What is Embolism?

Embolism (obstruction of an artery, typically by a clot of blood or an air bubble) is found to be associated with 708 drugs and 920 conditions by eHealthMe. Check the latest studies of Embolism.

On Jul, 19, 2026

26,430 people reported to have side effects when taking Rivaroxaban.
Among them, 65 people (0.25%) have Embolism.

Among these 65 people:

How long have people been on Rivaroxaban when they have Embolism? *

What is the gender of people who have Embolism when taking Rivaroxaban? *

female: 63.64 %
male: 36.36 %

What is the age of people who have Embolism when taking Rivaroxaban? *

What are other drugs people take besides Rivaroxaban? *

What are other side effects people have besides Embolism? *

Drug Ineffective: 6 people, 9.23%
Encephalopathy (functioning of the brain is affected by some agent or condition): 5 people, 7.69%
Oedema Peripheral (superficial swelling): 5 people, 7.69%
Pulmonary Embolism (blockage of the main artery of the lung): 4 people, 6.15%
Haemorrhage (bleeding): 4 people, 6.15%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 3 people, 4.62%
Diarrhea: 3 people, 4.62%
Cellulitis (infection under the skin): 3 people, 4.62%
Infection: 3 people, 4.62%
Pneumonia: 3 people, 4.62%

What are the existing conditions these people have? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 11 people, 16.92%
High Blood Pressure: 10 people, 15.38%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 7 people, 10.77%
Pain: 7 people, 10.77%
Nausea And Vomiting: 5 people, 7.69%
Thrombosis (formation of a blood clot inside a blood vessel): 5 people, 7.69%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 5 people, 7.69%
Muscle Spasms (muscle contraction): 5 people, 7.69%
Nausea (feeling of having an urge to vomit): 5 people, 7.69%
Multiple Myeloma (cancer of the plasma cells): 4 people, 6.15%

* Approximation only. Some reports may have incomplete information.

Do you take Rivaroxaban and have Embolism?

- Check whether Embolism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rivaroxaban:

Rivaroxaban (26,544 reports)

Embolism treatments and more:

Embolism (13,418 reports)

Browse all side effects of Rivaroxaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Embolism:

Embolism (708 drugs)

Browse all the conditions that are associated with Embolism:

Embolism (920 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rivaroxaban (the active ingredients of Rivaroxaban) and Rivaroxaban (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.